The Risks of Splitting the MMR Vaccine: Historical Insights and Implications
Splitting the MMR vaccine could lead to missed doses and increased illness among children, echoing past lessons from vaccine history.
August 11, 2026
Finance
Financial news, markets, and business updates
FDA Rejection Hits Radiopharma; Hims & Hers Eyes Peptides Market
FDA nixes a radiopharma drug by ITM Isotope Technologies, while Hims & Hers plans to enter the peptides market amidst evolving regulations.
August 11, 2026
MoonLake Immunotherapeutics' Ambiguous Data Raises Concerns in Drug Development
MoonLake Immunotherapeutics faces scrutiny for vague disclosures on its autoimmune drug candidate, raising questions about its trial results’ credibility.
August 11, 2026
Nurses Advocate for Involvement in Clinical AI Development Amid Growing Concerns
Nurses are increasingly spotlighting the risks of clinical AI, advocating for a collaborative approach to its development and deployment in healthcare.
August 11, 2026
Challenges Ahead for Medicare's New GLP-1 Weight Loss Drug Program
Medicare's “Bridge” program aims to lower costs for GLP-1 medications, yet its complexity may hinder patient access to affordable treatments.
August 11, 2026
FDA Denies Approval for ITM-11, a Radiopharmaceutical Therapy Set to Compete with Novartis
The FDA has rejected ITM-11 due to manufacturing concerns, hindering its potential as a competitor to Novartis’ treatment for rare neuroendocrine tumors.
August 10, 2026
New FDA Requirements on Food Additives Demand Transparency from Manufacturers
The FDA now requires manufacturers to disclose food additive details, enhancing oversight for substances previously lacking regulation.
August 10, 2026
Replimune’s Melanoma Drug Approved Amid Medicare Policy Shift Impacting Price Negotiations
Replimune's new melanoma treatment gains FDA approval, while a Medicare policy change delays price negotiations for AbbVie drugs.
August 07, 2026
Boston's Biotech Scene Faces New Challenges Amid a Changing Landscape
As Boston's biotech sector grapples with talent migration to California, new discoveries in Alzheimer's research signal both change and opportunity.
August 07, 2026
Why a Boston-Bred Biotech Founder Chose California for His Startup
Felix Wong's biotech startup thrives in California's culture despite his Massachusetts roots and impressive academic pedigree.
August 07, 2026
Replimune's Tumultuous Journey Ends with FDA Approval of Melanoma Treatment
Replimune's advanced melanoma drug, RP1, receives FDA approval after a challenging path, bringing hope to patients with a hefty price tag.
August 06, 2026
FDA Grants Approval for New Drug and Vaccine, Impacting Biotech Landscape
The FDA has recently approved a new therapeutic drug and a vaccine, shaping the future direction of biotechnology and addressing pressing health needs.
August 06, 2026
FDA Approval of Takeda's Orzeyful Marks a Shift in Narcolepsy Treatment
The FDA has approved Takeda's Orzeyful, a new orexin receptor agonist that promises to improve daytime alertness for narcolepsy patients.
August 05, 2026
Scrutiny Grows on Chinese Gene-Editing Trials Following Child's Death
A child’s death in a CRISPR gene-editing trial by HuidaGene raises serious concerns about safety and regulatory oversight in China’s biotech sector.
August 05, 2026
Moderna Initiates First Clinical Trial for Ebola mRNA Vaccine
Moderna has launched a clinical trial for its mRNA-based Ebola vaccine, marking a significant step in combating this viral disease.
August 05, 2026
Reassessing AI Potential: Insights from Schrödinger’s CEO Ramy Farid
Ramy Farid of Schrödinger reflects on the evolving role of AI in biotech, envisioning clearer perceptions in the industry within five years.
August 05, 2026
Medicare Pilot and Pharma Developments: Key Updates on Orphan Drugs and Merger Talks
A recent Medicare pilot proposal risks reducing savings for retail drugs. Meanwhile, merger talks between AstraZeneca and Bristol Myers Squibb have been denied.
August 05, 2026
Impact of Excluding Rare Disease Treatments from Medicare Drug Pricing Pilots
Excluding rare disease therapies from Medicare's drug pricing pilots could significantly reduce overall savings, according to recent research.
August 05, 2026
Rethinking Prostate Cancer Diagnosis: The Role of MRI vs. Traditional Methods
Despite high diagnosis rates, many U.S. men miss out on MRI screenings for prostate cancer, which could lead to better outcomes.
August 05, 2026
Novo Nordisk's Heart Drug Fails to Reduce Major Cardiac Events in Key Trial
Novo Nordisk's ziltivekimab, aimed at targeting inflammation, showed no reduction in cardiovascular events despite lowering inflammation markers.
July 31, 2026